{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T13:29:02Z","timestamp":1781011742936,"version":"3.54.1"},"reference-count":18,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"6","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncology Practice"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec><jats:title>PURPOSE:<\/jats:title><jats:p> We surveyed oncologists who treat classic Hodgkin lymphoma (cHL) as part of the CONNECT study to understand the treatment decision\u2010making process, including the impact of positron emission tomography\/computed tomography (PET\/CT) imaging. <\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p> US physicians self-identifying as oncologists, hematologists, or hematologists\/oncologists with \u22652 years of practice experience who treated \u22651 adult with stage III\/IV cHL in the frontline setting in the last year were surveyed (October 19-November 16, 2020). Physician demographics, guideline adherence, and PET\/CT utilization, interpretation, and access barriers were assessed. <\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p> In total, 301 physicians participated in the survey. Eighty-eight percent of physicians gave somewhat-to-significant consideration to NCCN guidelines. Most physicians (94%; n = 284) reported obtaining a PET\/CT scan at diagnosis; of these physicians, 97% reported obtaining an interim PET\/CT scan for stage III\/IV cHL, with 65% typically obtaining an interim PET\/CT scan after cycle 2. The Deauville 5-point scale (5PS) was the primary scoring system used to review PET\/CT results by 62% of physicians, with a positive score defined as \u22653 by 44%, \u22654 by 37%, and \u22652 by 12% of physicians. Fifty-five percent of physicians reported difficulty in obtaining PET\/CT scans. <\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION:<\/jats:title><jats:p> Although most physicians considered NCCN guidelines when treating patients with stage III\/IV cHL, interim PET\/CT scans after cycle 2 were not universally obtained. When PET\/CT scans were obtained, Deauville 5PS scores were not always provided, and variability existed on what defined a positive score. These findings suggest that opportunities exist for education and improved PET-adapted treatment approaches. <\/jats:p><\/jats:sec>","DOI":"10.1200\/op.22.00811","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T19:59:10Z","timestamp":1679515150000},"page":"e867-e876","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":6,"title":["Observations of Oncologists on Treatment Selection With Interim Positron Emission Tomography\u2013Adapted Approaches in Classic Hodgkin Lymphoma: The Real-World CONNECT Study"],"prefix":"10.1200","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0282-6490","authenticated-orcid":false,"given":"Susan K.","family":"Parsons","sequence":"first","affiliation":[{"name":"Tufts Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8057-9897","authenticated-orcid":false,"given":"Kristina S.","family":"Yu","sequence":"additional","affiliation":[{"name":"Seagen Inc., Bothell, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2468-9482","authenticated-orcid":false,"given":"Nicholas","family":"Liu","sequence":"additional","affiliation":[{"name":"Seagen Inc., Bothell, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriya","family":"Kumar","sequence":"additional","affiliation":[{"name":"Ipsos Healthcare, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Fanale","sequence":"additional","affiliation":[{"name":"Seagen Inc., Bothell, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Holmes","sequence":"additional","affiliation":[{"name":"Ipsos Healthcare, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0574-4258","authenticated-orcid":false,"given":"Carlos","family":"Flores","sequence":"additional","affiliation":[{"name":"Genesis Research, Hoboken, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0743-7219","authenticated-orcid":false,"given":"Andy","family":"Surinach","sequence":"additional","affiliation":[{"name":"Genesis Research, Hoboken, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3914-9534","authenticated-orcid":false,"given":"Darcy R.","family":"Flora","sequence":"additional","affiliation":[{"name":"GRYT Health, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6900-1824","authenticated-orcid":false,"given":"Andrew M.","family":"Evens","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/920898"},{"key":"b2","volume-title":"Section 32: Adolescent and Young Adult Cancer by Site Incidence, Survival and Mortality","author":"National Cancer Institute"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0021"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20684"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1177\/1179554917731072"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25071"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.103218"},{"key":"b8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510093"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.1119"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2961-x"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17051783"},{"key":"b12","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3891"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0026"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162556"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00102-2"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206125"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-140698"},{"key":"b19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.12.012"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP.22.00811","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T22:01:28Z","timestamp":1686607288000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP.22.00811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1200\/OP.22.00811"],"URL":"https:\/\/doi.org\/10.1200\/op.22.00811","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"2022-12-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}